Program Overview

Managing Myelodysplasia – Promise or Practice? Demythologizing DNA Demethylation and Other New Therapies will utilize a case-based format to explore the current and developing treatment options for myelodysplastic syndromes. Clinically relevant information about new molecular diagnostic techniques,effective supportive care,and aggressive interventional maneuvers is included.

Target Audience

Medical Oncologists and Hematologists

Learning Objectives

At the conclusion of this educational activity, participants should be better able to:

• Discuss current standards of care in hematologic malignancies,specifically myelodysplastic syndromes.
• Identify which new therapies are appropriate for integration into the care of MDS patients.
• Describe the most important presentations given at ASH in 2005 in the field of MDS and patient care.
• Evaluate novel and emerging therapies in the treatment of MDS.
• Consider the role of all therapies in each variation of MDS.

Sponsorship

This activity is jointly sponsored by The American School of Oncology™ and Medical Education Collaborative®.

Support for this program has been provided by an educational grant from Pharmion.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and the American School of Oncology. MEC is accredited by the ACCME to provide continuing medical education for physicians.

This activity is approved for 1.75 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This activity includes both a monograph and a CD-ROM. Participants can choose which method they prefer to take the activity for CME; however credit will only be given for one method. Participants will not receive credit for both the monograph and the CD-ROM. For questions regarding the accreditation of this program, please contact Medical Education Collaborative at 303.420.3252. In order to receive credit, participants must score at least 70% on the post test and submit it along with the credit application and evaluation form to the address/fax number indicated. Statements of credit will be mailed within 6 to 8 weeks following the completion of the activity.

Disclaimer Statement

Medical information is ever-changing,transformed frequently by new research and clinical experience. While Medical Education Collaborative, Inc. makes every effort to present accurate information, no warranty, expressed or implied, is offered. Furthermore, the user should also use his/her own judgment, knowledge, experience,and diagnostic decision-making before applying any information, whether provided by MEC,other users, or third parties,to any professional or personal use.

The information contained and displayed within this enduring material is provided solely for educational and discussion purposes.

Chairperson

Jerry L. Spivak, MD
Professor of Medicine and Oncology
Johns Hopkins University
Baltimore, Maryland

Faculty

Larry D. Cripe, MD
Associate Professor of Medicine
Indiana University Cancer Center
Indianapolis, Indiana

Daniel J. DeAngelo, MD, PhD
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts

John M. McCarty, MD
Medical Director
Bone Marrow Transplantation Program
Massey Cancer Center at VCU Medical Center
Richmond, Virginia

Mikkael A. Sekeres, MD
Assistant Professor of Medicine
Cleveland Clinic
Cleveland, Ohio

Lewis R. Silverman, MD
Assistant Professor of Medicine
Mount Sinai School of Medicine
New York, New York

Disclosure Summary

Medical Education Collaborative,Inc. (MEC) is committed to the provision of CME that is balanced,objective,and evidence based. MEC adheres to Accreditation Council for Continuing Medical Education (ACCME) Essentials and Standards. Accordingly, all parties involved in content development have disclosed any real or apparent conflicts of interest relating to the topics of this educational activity, and the disclosure summary follows. MEC has established mechanisms to resolve conflicts of interest should they arise. Participants in MEC CME programs are afforded the opportunity to provide feedback on the quality of individual programs.

The employees of Medical Education Collaborative have no financial relationships to disclose.

The following faculty disclosures have been provided:

 

Larry Cripe, MD
Indiana University Cancer Center
The presenter, Larry Cripe, MD, receives grant/research support from Celgene, Johnson and Johnson, and Pharmion.

Daniel DeAngelo, MD
Dana-Farber Cancer Institute
The presenter, Daniel DeAngelo, MD, to the best of his knowledge, has no conflict of interest.

John McCarty, MD
Massey Cancer Center at VCU Medical Center
The presenter, John McCarty, MD, to the best of his knowledge, has no conflict of interest.

Mikkael Sekeres, MD
Cleveland Clinic
The presenter, Mikkael Sekeres, MD, receives grant/research support from Celgene and honoraria from Celgene and Pharmion.

Lewis Silverman, MD
Mount Sinai School of Medicine
The presenter, Lewis Silverman, MD, receives grant/research support from Celgene and Pharmion.

Jerry Spivak, MD
Johns Hopkins University
The chairperson, Jerry Spivak, MD, is a consultant to Novartis and Roche.